Long-term effects of therapeutic vaccination with rgp 120

AIDS

Volumn 14, Issue 2, 2000, Pages 203-204

  Lindenburg, Karen ^a   Langendam, Miranda W ^a   Veenstra, Jan ^a   Miedema, Frank ^b   Coutinho, Roel ^a,b  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETTER; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; FOLLOW-UP STUDIES; HIV ENVELOPE PROTEIN GP120; HUMANS; RECOMBINANT PROTEINS; TIME FACTORS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0033999147     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00017     Document Type: Letter

References (3)